StockData
Rani Therapeutics Holdings, Inc. logo

Rani Therapeutics Holdings, Inc. (RANI) stock

RANINasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 3/3051% above fair value
$0.58−0.07 (-10.42%)

Close on Nov 19, 2026Market cap $80.93MP/E –Yield –

Rani Therapeutics free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Rani Therapeutics's free cash flow for the twelve months ending Jun 30, 2026 was -$20.34M. For fiscal 2025 it was -$18.80M. The highest annual figure on record is -$16.16M in fiscal 2020.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$18.80M–
FY2024Dec 31, 2024-$35.76M–
FY2023Dec 31, 2023-$52.47M–
FY2022Dec 31, 2022-$48.13M–
FY2021Dec 31, 2021-$32.75M–
FY2020Dec 31, 2020-$16.16M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$9.06M–
Q1 FY2026Mar 31, 2026-$6.51M–
Q4 FY2025Dec 31, 2025$294.00K–
Q3 FY2025Sep 30, 2025-$5.06M–
Q2 FY2025Jun 30, 2025-$5.83M–
Q1 FY2025Mar 31, 2025-$8.20M–
Q4 FY2024Dec 31, 2024-$8.69M–
Q3 FY2024Sep 30, 2024-$8.54M–
Q2 FY2024Jun 30, 2024-$9.12M–
Q1 FY2024Mar 31, 2024-$9.42M–
Q4 FY2023Dec 31, 2023-$12.65M–
Q3 FY2023Sep 30, 2023-$14.78M–
Q2 FY2023Jun 30, 2023-$12.64M–
Q1 FY2023Mar 31, 2023-$12.40M–
Q4 FY2022Dec 31, 2022-$15.16M–
Q3 FY2022Sep 30, 2022-$12.65M–
Q2 FY2022Jun 30, 2022-$10.71M–
Q1 FY2022Mar 31, 2022-$9.61M–
Q4 FY2021Dec 31, 2021-$11.72M–
Q3 FY2021Sep 30, 2021-$11.12M-1759.7%
Q2 FY2021Jun 30, 2021-$5.76M–
Q1 FY2021Mar 31, 2021-$4.15M–
Q4 FY2020Dec 31, 2020-$6.96M–
Q3 FY2020Sep 30, 2020$670.00K–

More Rani Therapeutics figures

See a number that looks wrong?